Listed by the USPTO as HAGOPIAN, CASEY SHEA
Tech Center 1600 • Art Units: 1611 1615 1616 1617
This examiner grants 54% of resolved cases
HAGOPIAN, CASEY SHEA is a USPTO patent examiner in Tech Center 1600 and Art Unit 1611. The profile covers 574 resolved cases, with an allowance rate of 54.2% and a median of 1218 days to allowance. The interview lift of 33.8% indicates that interviews are associated with a meaningful improvement in allowance outcomes within this resolved-case record.
The portfolio includes 3M Company, The Regents of the University of California, and Globus Medical Inc. Representative firms are Knobbe, Martens, Olson & Bear, LLP, Norton Rose Fulbright US LLP, and SUGHRUE MION, PLLC. Practitioners handling matters in this docket can use the profile to anticipate a moderate allowance environment and to evaluate whether interview preparation should be part of prosecution planning.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17671071 | ENGINEERED SCAFFOLDS FOR VASCULARIZED TISSUE REPAIR | Final Rejection | The Regents of the University of California |
| 18046281 | Thermoresponsive or Shear-Thinning Injectable Gel Compositions for Treatment of Arthritis | Final Rejection | GLOBUS MEDICAL, INC. |
| 19119944 | ANTIMICROBIAL COMPOSITIONS AND ARTICLES MADE THEREFROM | Non-Final OA | Solventum Intellectual Properties Company |
| 18870174 | ANTIMICROBIAL COMPOSITIONS AND ARTICLES MADE THEREFROM | Non-Final OA | Solventum Intellectual Properties Company |
| 18875297 | ORAL CARE COMPOSITION COMPRISING A PEROXIDE AND AN ETHYLENE OXIDE/PROPYLENE OXIDE BLOCK COPOLYMER | Non-Final OA | BASF SE |
| 18286541 | BIOCHEMICAL ACTIVATION OF DYSFUNCTIONAL SKELETAL STEM CELLS FOR SKELETAL REGENERATION | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 18660711 | Silicone-Free Hair Conditioner | Non-Final OA | Henkel AG & Co. KGaA |
| 18120726 | USE OF THERMOLYSIN TO REDUCE OR ELIMINATE BACTERIAL BIOFILMS FROM SURFACES | Final Rejection | SMITH & NEPHEW, INC. |
| 18995446 | HYALURONIC ACID DERIVATIVE PHARMACEUTICAL COMPOSITION AND PHARMACEUTICAL COMPOSITION | Non-Final OA | ASAHI KASEI KABUSHIKI KAISHA |
| 19045529 | ENDOSCOPE VISUAL FIELD-SECURING VISCOELASTIC COMPOSITION | Non-Final OA | Otsuka Pharmaceutical Factory, Inc. |
| 18860152 | Makeup Composition Comprising a Polyphenol, a Polyoxyalkylenated or Polyglycerolated Compound, a Monoalcohol and an Acid, and Method Employing Same | Non-Final OA | L'OREAL |
| 18721360 | METHOD OF FORMING A READY-TO-USE AGRICULTURAL COMPOSITION COMPRISING GLUFOSINATE | Non-Final OA | NOURYON CHEMICALS INTERNATIONAL B.V. |
| 17753790 | HIGH LOAD FORMULATION CONTAINING A SULFOPOLYMER | Non-Final OA | Eastman Chemical Company |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy54.2% of resolved applications examined by Casey Shea Hagopian were allowed (574 resolved cases), compared with 35.4% across Art Unit 1611 over the last five years.
This examiner's interview lift is +33.8 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Casey Shea Hagopian took 1,218 days on average from filing to allowance.
Casey Shea Hagopian examines applications in Art Unit 1611 in Tech Center 1600 (Biotechnology & Pharmaceuticals).